NASDAQ:ABMD - ABIOMED Stock Price, News, & Analysis

ABIOMED trades on the NASDAQ under the ticker symbol "ABMD."

ABIOMED, Inc. (NASDAQ:ABMD) announced its earnings results on Thursday, July, 26th. The medical equipment provider reported $1.95 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.80 by $1.15. The medical equipment provider earned $180.01 million during the quarter, compared to analysts' expectations of $173.87 million. ABIOMED had a return on equity of 18.91% and a net margin of 25.71%. The company's quarterly revenue was up 35.9% on a year-over-year basis. During the same quarter last year, the business posted $0.82 earnings per share. View ABIOMED's Earnings History.

ABIOMED is scheduled to release their next quarterly earnings announcement on Thursday, October, 25th 2018. View Earnings Estimates for ABIOMED.

8 brokerages have issued twelve-month price objectives for ABIOMED's stock. Their forecasts range from $280.00 to $480.00. On average, they expect ABIOMED's share price to reach $363.1429 in the next year. This suggests a possible upside of 0.2% from the stock's current price. View Analyst Price Targets for ABIOMED.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ABIOMED in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ABIOMED.

Some companies that are related to ABIOMED include Becton Dickinson and (BDX), Stryker (SYK), Boston Scientific (BSX), FRESENIUS SE &/S (FSNUY), Baxter International (BAX), ResMed (RMD), DexCom (DXCM), Teleflex (TFX), Hill-Rom (HRC), ICU Medical (ICUI), Integra Lifesciences (IART), Haemonetics (HAE), Globus Medical (GMED), Insulet (PODD) and Penumbra (PEN).

News stories about ABMD stock have been trending somewhat positive on Tuesday, Accern Sentiment Analysis reports. Accern identifies negative and positive press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. ABIOMED earned a coverage optimism score of 0.23 on Accern's scale. They also gave media stories about the medical equipment provider an impact score of 47.06 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next several days. View Recent Headlines for ABIOMED.

ABIOMED's stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.30%), Baillie Gifford & Co. (4.72%), Renaissance Technologies LLC (3.46%), FMR LLC (1.54%), Bank of New York Mellon Corp (1.43%) and Waddell & Reed Financial Inc. (1.01%). Company insiders that own ABIOMED stock include Andrew J Greenfield, David M Weber, Dorothy E Puhy, Eric A Md Rose, Martin P Sutter, Michael G Howley, Michael R Minogue, Paul Thomas and William J Bolt. View Institutional Ownership Trends for ABIOMED.

ABMD stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Winslow Capital Management LLC, Winslow Capital Management LLC, American Century Companies Inc., Bank of New York Mellon Corp, Janus Henderson Group PLC, OppenheimerFunds Inc. and Castleark Management LLC. Company insiders that have sold ABIOMED company stock in the last year include Andrew J Greenfield, David M Weber, Dorothy E Puhy, Eric A Md Rose, Martin P Sutter, Michael G Howley, Michael R Minogue and William J Bolt. View Insider Buying and Selling for ABIOMED.

ABMD stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, FMR LLC, Carillon Tower Advisers Inc., Sumitomo Mitsui Trust Holdings Inc., Massachusetts Financial Services Co. MA, Advisors Asset Management Inc., Schwab Charles Investment Management Inc. and Nomura Holdings Inc.. View Insider Buying and Selling for ABIOMED.

Shares of ABMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of ABMD stock can currently be purchased for approximately $362.48.

ABIOMED has a market capitalization of $16.96 billion and generates $593.75 million in revenue each year. The medical equipment provider earns $112.17 million in net income (profit) each year or $2.45 on an earnings per share basis. ABIOMED employs 1,143 workers across the globe.

ABIOMED's mailing address is 22 CHERRY HILL DR, DANVERS MA, 01923. The medical equipment provider can be reached via phone at 978-646-1400 or via email at [email protected]